The Goldman Sachs Group Cuts Silence Therapeutics (NASDAQ:SLN) Price Target to $4.00

Silence Therapeutics (NASDAQ:SLN) had its target price lowered by The Goldman Sachs Group from $6.00 to $4.00 in a research note published on Tuesday morning,Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

Other research analysts have also issued reports about the company. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Stock Up 0.2 %

NASDAQ:SLN opened at $4.74 on Tuesday. Silence Therapeutics has a 12-month low of $4.06 and a 12-month high of $27.72. The firm has a market capitalization of $141.87 million, a P/E ratio of -3.02 and a beta of 1.08. The stock’s fifty day simple moving average is $5.44 and its 200-day simple moving average is $11.48.

Institutional Trading of Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC raised its stake in shares of Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after purchasing an additional 2,793 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $26,000. Y Intercept Hong Kong Ltd raised its stake in shares of Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock valued at $383,000 after purchasing an additional 3,923 shares during the period. GAMMA Investing LLC raised its stake in shares of Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in shares of Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after purchasing an additional 6,098 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.